From Phase II studies as well as the Phase III Oral Solo trial (presented at the ACR last November), the agent has proven to be clinically potent and rapidly effective.
Results from Phase II trials indicate that this oral version has comparable effectiveness to Taxol, but does not have the side effects associated with prolonged infusions.
The companies will join forces to develop and commercialize ertugliflozin (PF-04971729), an oral sodium glucose cotransporter (SGLT2) inhibitor for type 2 diabetes which is about to begin phase 3 studies.